Stay updated on Rucaparib and Nivolumab Combo in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Rucaparib and Nivolumab Combo in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Rucaparib and Nivolumab Combo in Solid Tumors Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.2%
    Check dated 2024-06-13T23:15:14.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to evaluating Rucaparib in combination with Nivolumab in patients with selected solid tumors, specifically high-grade serous or endometroid ovarian cancer.
    Difference
    0.2%
    Check dated 2024-06-06T14:39:17.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria for clinical research, including examples such as general health condition or prior treatments. The new text also provides a link for general information about clinical research.
    Difference
    18%
    Check dated 2024-05-22T20:58:20.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:21:23.000Z thumbnail image

Stay in the know with updates to Rucaparib and Nivolumab Combo in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Rucaparib and Nivolumab Combo in Solid Tumors Clinical Trial page.